SPRED1 and neoplasm: Overall, all but one tumor (66/67) had at least one well-established driver gene mutation (Fig. 6a), i.e. MAPK pathway (NF1, NRAS, KIT, BRAF), SF3B1, TP53 and MDM2, SPRED1, TERT and ATRX, CDK4 and CCND1 (Fig. 6b).